MediciNova (MNOV) Projected to Release Quarterly Earnings on Thursday

Key Points

• MediciNova is expected to report Q3 2026 results after market close on November 12, with analysts forecasting a loss of $0.06 per share and revenue of $0.05 million; its earnings call is scheduled for November 13.
• In its prior quarter, the company reported a loss of $0.05 per share, beating the $0.06 loss analysts expected, and revenue of $0.46 million versus a $0.07 million estimate.
• Analysts give MNOV a consensus “Moderate Buy” rating and an average price target of $7.75. Major shareholder 3D Investment Partners recently sold 640,000 shares, reducing its position by 11.63%.

MediciNova (NASDAQ:MNOV - Get Free Report) is anticipated to announce its Q3 2026 results after the market closes on Thursday, November 12th. Analysts expect the company to post earnings of ($0.06) per share and revenue of $0.05 million for the quarter. Investors are encouraged to explore the company's upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Friday, November 13, 2026 at 4:00 PM ET.

MediciNova (NASDAQ:MNOV - Get Free Report) last announced its earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.06) by $0.01. The firm had revenue of $0.46 million for the quarter, compared to analyst estimates of $0.07 million. MediciNova had a negative net margin of 1,168.70% and a negative return on equity of 26.51%. On average, analysts expect MediciNova to post ($0.25) EPS for the current fiscal year and ($0.51) EPS for the next fiscal year.

MediciNova Stock Up 2.1%

Shares of MNOV opened at $1.45 on Thursday. MediciNova has a twelve month low of $1.22 and a twelve month high of $3.90. The stock's fifty day simple moving average is $1.79 and its 200 day simple moving average is $1.51.

Insider Buying and Selling at MediciNova

In related news, major shareholder 3D Investment Partners Pte. Lt sold 640,000 shares of the stock in a transaction dated Friday, September 25th. The shares were sold at an average price of $2.70, for a total transaction of $1,728,000.00. Following the completion of the sale, the insider owned 4,862,047 shares in the company, valued at $13,127,526.90. This trade represents a 11.63% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 14.00% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have commented on MNOV. HC Wainwright reaffirmed a "buy" rating on shares of MediciNova in a report on Tuesday, September 29th. Roth Capital initiated coverage on shares of MediciNova in a research note on Thursday, September 17th. They set a "buy" rating and a $6.00 price objective on the stock. Finally, Weiss Ratings upgraded MediciNova from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Wednesday, September 2nd. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $7.75.

About MediciNova

MediciNova, Inc NASDAQ: MNOV is a clinical-stage biopharmaceutical company based in San Diego, California. The company develops small-molecule therapies for diseases with significant unmet medical needs, with a primary focus on neurological, neurodegenerative, and other serious medical conditions.

Its lead development program is MN-166, also known as ibudilast, an orally administered compound with anti-inflammatory and neuroprotective properties. MediciNova has evaluated ibudilast in clinical studies for conditions including progressive multiple sclerosis, amyotrophic lateral sclerosis, and substance use disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.